These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27369381)

  • 21. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
    Zhao XZ; Maddali K; Metifiot M; Smith SJ; Vu BC; Marchand C; Hughes SH; Pommier Y; Burke TR
    Chem Biol Drug Des; 2012 Feb; 79(2):157-65. PubMed ID: 22107736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.
    Anstett K; Brenner B; Mesplède T; Wainberg MA
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.
    Engelman AN
    J Biol Chem; 2019 Oct; 294(41):15137-15157. PubMed ID: 31467082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
    Ammar FF; Abdel-Azeim S; Zargarian L; Hobaika Z; Maroun RG; Fermandjian S
    PLoS One; 2012; 7(7):e40223. PubMed ID: 22768342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site.
    Johnson AA; Sayer JM; Yagi H; Patil SS; Debart F; Maier MA; Corey DR; Vasseur JJ; Burke TR; Marquez VE; Jerina DM; Pommier Y
    J Biol Chem; 2006 Oct; 281(43):32428-38. PubMed ID: 16943199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
    Savarino A
    Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
    Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
    Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
    J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    Oliveira M; Ibanescu RI; Pham HT; Brenner B; Mesplède T; Wainberg MA
    AIDS; 2016 Sep; 30(15):2267-73. PubMed ID: 27367488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
    Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
    Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33572956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.
    Hare S; Vos AM; Clayton RF; Thuring JW; Cummings MD; Cherepanov P
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20057-62. PubMed ID: 21030679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
    Neogi U; Singh K; Aralaguppe SG; Rogers LC; Njenda DT; Sarafianos SG; Hejdeman B; Sönnerborg A
    AIDS; 2018 Feb; 32(4):469-476. PubMed ID: 29239896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence.
    Thierry E; Lebourgeois S; Simon F; Delelis O; Deprez E
    Sci Rep; 2017 Oct; 7(1):14067. PubMed ID: 29070877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays.
    Johnson AA; Marchand C; Patil SS; Costi R; Di Santo R; Burke TR; Pommier Y
    Mol Pharmacol; 2007 Mar; 71(3):893-901. PubMed ID: 17172465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.